Literature DB >> 29143081

Generation in yeast and antigenic characterization of hepatitis E virus capsid protein virus-like particles.

Martynas Simanavicius1, Paulius Lukas Tamosiunas2, Rasa Petraityte-Burneikiene2, Reimar Johne3, Rainer G Ulrich4,5, Aurelija Zvirbliene2, Indre Kucinskaite-Kodze2.   

Abstract

Hepatitis E is a globally distributed human disease caused by hepatitis E virus (HEV). In Europe, it spreads through undercooked pork meat or other products and with blood components through transfusions. There are no approved or golden standard serologic systems for HEV diagnostics. Commercially available HEV tests often provide inconsistent results which may differ among the assays. In this study, we describe generation in yeast and characterization of HEV genotype 3 (HEV-3) and rat HEV capsid proteins self-assembled into virus-like particles (VLPs) and the development of HEV-specific monoclonal antibodies (MAbs). Full-length HEV-3 and rat HEV capsid proteins and their truncated variants comprising amino acids (aa) 112-608 were produced in yeast S. cerevisiae. The yeast-expressed rat HEV capsid protein was found to be glycosylated. The full-length HEV-3 capsid protein and both full-length and truncated rat HEV capsid proteins were capable to self-assemble into VLPs. All recombinant proteins contained HEV genotype-specific linear epitopes and cross-reactive conformational epitopes recognized by serum antibodies from HEV-infected reservoir animals. Two panels of MAbs against HEV-3 and rat HEV capsid proteins were generated. Their cross-reactivity pattern was investigated by Western blot, ELISA, and immunofluorescence assay on HEV-3-infected cell cultures. The analysis revealed cross-reactive, genotype-specific, and virus-reactive MAbs. MAb epitopes were localized within S, M, and P domains of HEV-3 and rat HEV capsid proteins. Yeast-generated recombinant VLPs of HEV-3 and rat HEV capsid proteins and HEV-specific MAbs might be employed to develop novel HEV detection systems.

Entities:  

Keywords:  Capsid protein; HEV genotype 3; Hepatitis E virus (HEV); Monoclonal antibodies; Rat HEV; Virus-like particles

Mesh:

Substances:

Year:  2017        PMID: 29143081     DOI: 10.1007/s00253-017-8622-9

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  4 in total

1.  Efficient Production of Chimeric Hepatitis B Virus-Like Particles Bearing an Epitope of Hepatitis E Virus Capsid by Transient Expression in Nicotiana benthamiana.

Authors:  Gergana Zahmanova; Milena Mazalovska; Katerina Takova; Valentina Toneva; Ivan Minkov; Hadrien Peyret; George Lomonossoff
Journal:  Life (Basel)       Date:  2021-01-17

2.  Molecular Characterization and Seroprevalence of Hepatitis E Virus in Inflammatory Bowel Disease Patients and Solid Organ Transplant Recipients.

Authors:  Juozas Grigas; Maria Montoya; Evelina Simkute; Marius Buitkus; Ruta Zagrabskaite; Arnoldas Pautienius; Dainius Razukevicius; Laimas Virginijus Jonaitis; Gediminas Kiudelis; Jurgita Skieceviciene; Ruta Vaiciuniene; Asta Stankuviene; Inga Arune Bumblyte; Juozas Kupcinskas; Arunas Stankevicius
Journal:  Viruses       Date:  2021-04-13       Impact factor: 5.048

3.  A broadly cross-reactive monoclonal antibody against hepatitis E virus capsid antigen.

Authors:  Barbara Kubickova; Jörg A Schenk; Franziska Ramm; Kornelija Markuškienė; Jochen Reetz; Paul Dremsek; Paulius Lukas Tamosiunas; Laima Cepulyte; Hoai Anh Trinh; Johannes Scholz; Henry Memczak; Marc Hovestädt; René Ryll; Rasa Petraityte-Burneikiene; Victor M Corman; Anika Andersson; Dietmar Becher; Martin H Groschup; Stefan Kubick; Frank Sellrie; Reimar Johne; Rainer G Ulrich
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-15       Impact factor: 4.813

4.  Mapping of Recognition Sites of Monoclonal Antibodies Responsible for the Inhibition of Pneumolysin Functional Activity.

Authors:  Indre Kucinskaite-Kodze; Martynas Simanavicius; Justas Dapkunas; Milda Pleckaityte; Aurelija Zvirbliene
Journal:  Biomolecules       Date:  2020-07-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.